What you get
Access The Pharma Letter's latest news free for 7 days
Saturday, October 5, 2013
Novartis presents strong new Ph III results with omalizumab in CSU - The Pharma Letter
05-10-2013
Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective and safe in the treatment of chronic spontaneous urticaria (CSU), a chronic and debilitating form of hives.
In order to access this content you need to be logged into the site and have an active subscription or trial subscription. Please login, take a free trial or subscribe in order to continue reading.
A trial subscription will give you access to the latest news on The Pharma Letter for 7 days, in order to evaluate the paid service.
PLUS... you can receive the Pharma Letter headlines and news roundup email free forever
Click here to take a free trial
What you get
Unlimited access to The Pharma Letter site for a whole year
Only £70 per month or £720 per year
- No-limits access to our the site with up-to-the minute news
- Personalised news and email alerts
- Online discussion forums and Q&A section
- RSS news feeds that you can add to your favourite reader, or website
- Daily news email alert, with the breaking news stories and news roundup
Click here to subscribe
"Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. Its part of the key information for keeping me informed"
Nigel Brooksby, Chairman, Sanofi aventis UK Ltd
Source : http://www.thepharmaletter.com/article/novartis-presents-strong-new-ph-iii-results-with-omalizumab-in-csu
